METASTATIC UROTHELIAL CARCINOMA
Clinical trials for METASTATIC UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bladder cancer drug combo study halted early – what we know
Disease control TerminatedThis study tested a combination of two drugs (pemigatinib and pembrolizumab) against pemigatinib alone or standard care for people with advanced bladder cancer that has a specific FGFR3 gene change and cannot take the chemotherapy cisplatin. The goal was to see if the combination…
Matched conditions: METASTATIC UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Bladder cancer combo trial halted after only 4 patients
Disease control TerminatedThis study tested a combination of two drugs, selinexor and pembrolizumab, in people with advanced bladder cancer who could not take or had stopped responding to the chemotherapy drug cisplatin. The goal was to find the best dose and see if the combination could shrink tumors. Ho…
Matched conditions: METASTATIC UROTHELIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mamta Parikh • Aim: Disease control
Last updated May 01, 2026 16:00 UTC